| OAE0205 | 'Endeavor to reach the furthest behind first': promoting HIV prevention services using social media intervention in the era of COVID 19 among FSW in Benue State | Oral abstract session with live Q&A | Optimizing HIV services (prevention, testing and/or treatment) in the COVID-19 era |
| OAE0302 | The effect of a conditional cash transfer program on AIDS morbidity and mortality among the poorest: a quasi-experimental study of a cohort of 22.7 million Brazilians | Oral abstract session with live Q&A | Social protection: New evidence and programmatic lessons |
| OAE0303 | Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for all infants born in high-burden settings | Oral abstract session with live Q&A | Economic evaluation and affordability assessments |
| OAE0304 | The relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis: a modelled economic evaluation and threshold analysis in South Africa based on the HPTN 083 and 084 trials | Oral abstract session with live Q&A | Economic evaluation and affordability assessments |
| OAE0305 | Variation in average unit prices (2020) of antiretroviral drugs in generic accessible low- and middle-income countries | Oral abstract session with live Q&A | Financing HIV, hepatitis and STI testing and drug access: The economics of generics and differential pricing structures |
| OAE0402 | Is local production of HIV commodities a feasible strategy for improving domestic ownership and financial sustainability of HIV epidemiological control in low- and middle-income settings? | Oral abstract session with live Q&A | Approaches to achieving sustainability, including sustainable financing for civil society |
| OAE0403 | Quantifying the health and economic impact of voluntary licensing of HIV medicines in low- and middle-income countries: putting numbers on additional uptake, deaths averted, and money saved by MPP licences | Oral abstract session with live Q&A | Financing HIV, hepatitis and STI testing and drug access: The economics of generics and differential pricing structures |
| OAE0404 | Estimated costs to address unmet financial needs for HIV pre-exposure prophylaxis, United States, 2018 | Oral abstract session with live Q&A | National financing analyses and financing mechanisms for HIV, hepatitis and STI programmes and services |
| OAE0405 | Thailand national PrEP program: moving towards sustainability | Oral abstract session with live Q&A | Implementation science of scaling up prevention (including PrEP) |
| OAE0406 | The economic returns of achieving the 2021-2030 AIDS targets to end the AIDS epidemic by 2030 | Oral abstract session with live Q&A | Economic evaluation and affordability assessments |